Litigation Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Docket		Date Filed	2015-08-05
Court	District Court, D. Delaware	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,733,783; 8,114,383; 8,309,060; 8,361,499; 8,529,948; 8,551,520; 8,647,667; 8,808,740; 9,023,401; 9,056,052; 9,060,940; 9,084,816; 9,095,614; 9,095,615; 9,198,863; 9,205,056; 9,675,610; 9,750,703
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-05	175		Hossein Omidian Regarding Invalidity of U.S. Patent Nos. 6,733,783; 8,361,499; 8,551,520; 8,647,667; 9,023,… 5 August 2015 1:15-cv-00687-GMS Patent None District Court, D. Delaware	External link to document
2015-08-05	177		Jacobs, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Mayersohn, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Muzzio, Ph.D. Concerning the Invalidity of U.S. Patent Nos. 8,529,948; 8,309,060; 9,084,816; 9,095,614…Ryu, Ph.D. Concerning the Indefiniteness of U.S. Patent Nos. 9,198,863 and 8,808,740 filed by Alvogen Pine… 5 August 2015 1:15-cv-00687-GMS Patent None District Court, D. Delaware	External link to document
2015-08-05	178		.S. Patent Nos. 6,733,783 ("the '783 patent"), 8,361,499 ("the '499 patent"… ORDER Construing the Terms of U.S. Patent Nos. 6,733,783, 8,361,499, 8,551.520, 8,647,667, 9,023,401… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 6,733,783, 8,361,499, 8,551.520, 8,647,667, 9,023,401…948 patent"), 8,808,740 ("the '740 patent"), 9,056,052 ("the '052 patent"…8,551,520 ("the '520 patent"), 8,647,667 ("the '667 patent"), 9,023,401 ("	External link to document

Purdue Pharma v. Alvogen Pine Brook: Hysingla ER Patent Litigation Summary

Last updated: August 2, 2026

Purdue Pharma L.P. v. Alvogen Pine Brook LLC, No. 1:15-cv-00687-GMS, was an ANDA patent case concerning Alvogen’s proposed generic version of Hysingla ER, Purdue’s extended-release hydrocodone bitartrate product. Purdue asserted abuse-deterrent controlled-release formulation patents after Alvogen filed a Paragraph IV certification. The case was filed in the District of Delaware in 2015 before Judge Gregory M. Sleet and was later resolved without a public merits judgment establishing that Alvogen’s commercial product infringed.

What drug and formulation were at issue?

The case concerned Hysingla ER, an extended-release hydrocodone bitartrate tablet developed and marketed by Purdue.

Item	Details
Brand	Hysingla ER
Active ingredient	Hydrocodone bitartrate
Dosage form	Extended-release oral tablet
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Reference product sponsor	Purdue Pharma L.P.
Defendant and ANDA filer	Alvogen Pine Brook LLC
Court	U.S. District Court for the District of Delaware
Docket	No. 1:15-cv-00687-GMS
Filed	2015
Judge	Gregory M. Sleet
Patent technology	Abuse-deterrent controlled-release opioid formulations

Hysingla ER received FDA approval in November 2014 under NDA 206627. The product was designed to provide extended hydrocodone release and resist certain forms of physical and chemical manipulation. Its patent estate focused on the composition and performance of the dosage form rather than on hydrocodone itself, which is an older active pharmaceutical ingredient. (U.S. Food and Drug Administration, 2014)

What patents protected Hysingla ER in the Alvogen case?

Purdue’s case centered on patents covering abuse-deterrent controlled-release dosage forms containing an opioid active ingredient. The principal patent associated with the litigation was U.S. Patent No. 8,337,886.

Patent	Subject matter	Relevance
U.S. Patent No. 8,337,886	Abuse-deterrent controlled-release dosage forms	Core patent asserted against Alvogen
U.S. Patent No. 8,808,737	Related abuse-deterrent controlled-release technology	Part of the broader Hysingla ER patent position
Later continuation and related patents	Formulation and abuse-deterrence characteristics	Relevant to the broader Orange Book and market-entry analysis

The asserted claims covered dosage forms with controlled-release properties and resistance to common methods of abuse. The patent strategy was important because hydrocodone’s active ingredient was not itself a meaningful source of exclusivity. Purdue’s commercial protection depended on formulation, release behavior, and abuse-deterrence limitations.

Patent scope in ANDA litigation is determined by the claims identified in the complaint and the applicant’s Paragraph IV notice, not by the product label alone. The case therefore turned on whether Alvogen’s proposed formulation met the specific structural and functional limitations of Purdue’s claims.

How did the Paragraph IV challenge trigger the lawsuit?

Alvogen filed an ANDA seeking approval to market a generic Hysingla ER product. Its Paragraph IV certification asserted that the relevant Purdue patents were invalid, unenforceable, or not infringed.

Purdue responded by filing the Delaware action within the statutory 45-day period. The filing triggered the Hatch-Waxman litigation framework and imposed an FDA approval stay of up to 30 months, subject to statutory exceptions and any earlier court resolution.

The basic sequence was:

Event	Timing
Alvogen ANDA and Paragraph IV notice	Before Purdue’s complaint
Purdue complaint	2015
Statutory FDA stay	Potentially up to 30 months
Claim construction and merits proceedings	During the district-court case
Case disposition	Later resolved and closed without a publicly reported final merits judgment

The Paragraph IV filing created the legal controversy before Alvogen could launch. Purdue did not need to prove that Alvogen had already sold a product. It needed to show that the proposed ANDA product would infringe one or more patent claims if approved and marketed.

What were the main legal issues?

Claim construction

The litigation required the court to interpret technical terms defining the controlled-release and abuse-deterrent properties of the dosage form. Such terms can include limitations addressing:

• The identity and quantity of polymeric excipients.
• The physical structure of the tablet.
• Drug-release rates.
• Resistance to crushing, grinding, or extraction.
• The behavior of the dosage form in aqueous or alcoholic environments.
• Whether the formulation satisfies a claimed abuse-deterrence mechanism.

The construction of these terms determined whether Purdue’s claims reached Alvogen’s proposed generic formulation.

Infringement

Purdue’s infringement theory was based on the ANDA product and its proposed labeling. In an ANDA case, the court evaluates the product described in the application, including its formulation, manufacturing specifications, and intended uses.

A formulation patent can be infringed even when the generic sponsor changes inactive ingredients or manufacturing steps, provided the resulting product still falls within the patent claims. Conversely, a generic applicant can avoid infringement by designing around a structural limitation or by showing that a claimed functional property is absent.

Validity

Alvogen challenged the validity of Purdue’s patents. The likely grounds in this type of case included:

• Anticipation.
• Obviousness.
• Lack of written description.
• Enablement.
• Indefiniteness.

The central validity question was whether the claimed combination of opioid release control and abuse-deterrent characteristics represented a patentable formulation advance over prior controlled-release opioid technology.

Enforceability

The public record does not establish a final inequitable-conduct determination against Purdue in this docket. No public merits ruling should be treated as having invalidated the relevant Hysingla ER patents or found them unenforceable.

What was the litigation timeline?

Date	Development
November 2014	FDA approved Hysingla ER under NDA 206627.
2015	Alvogen filed an ANDA with a Paragraph IV certification.
2015	Purdue filed No. 1:15-cv-00687-GMS in the District of Delaware.
2015-2017	The parties litigated patent validity, infringement, and claim-construction issues.
2017-2018	The docket was resolved and ultimately closed.
After resolution	No publicly reported decision established an immediate Alvogen generic launch date.

The case formed part of a broader series of Hysingla ER ANDA actions brought by Purdue against multiple generic applicants. Parallel litigation was commercially significant because the same patent estate could delay or constrain more than one potential generic entrant.

What was the outcome of Purdue Pharma v. Alvogen?

The Alvogen case did not produce a publicly reported final trial judgment holding the asserted Hysingla ER patents invalid or definitively determining that Alvogen’s commercial product infringed.

The docket was resolved through a negotiated disposition rather than a published merits judgment. The material terms of any settlement or license arrangement were not publicly disclosed in the court record. As a result:

• There is no public finding that Alvogen’s ANDA product was invalidating prior art.
• There is no public finding that Purdue’s asserted patents were unenforceable.
• There is no public court judgment authorizing an unrestricted early generic launch.
• The economic and launch terms cannot be inferred from the docket closure alone.

For market analysis, the case should be classified as a resolved ANDA dispute, not as a precedent that invalidated Purdue’s Hysingla ER patent position.

What was the Orange Book status of Hysingla ER?

Hysingla ER was listed in the FDA Orange Book with patents directed to the product’s formulation and related characteristics. The Orange Book listings were more commercially important than any exclusivity tied to hydrocodone itself.

The relevant protection categories were:

1. Formulation patents covering the controlled-release dosage form.
2. Abuse-deterrence patents covering resistance to manipulation.
3. Method-of-use or labeling-related rights, where applicable.
4. Regulatory exclusivity associated with the initial NDA approval.

Orange Book listing does not by itself establish infringement. It identifies patents that an ANDA applicant must address through a certification. The ultimate effect depends on the claims, the Paragraph IV notice, litigation outcome, settlement terms, and any later patent listing or delisting.

When did Hysingla ER lose exclusivity?

Hysingla ER’s commercial exclusivity depended on several overlapping dates:

Exclusivity type	Commercial significance
New drug exclusivity	Delayed certain ANDA approvals after the NDA approval date
Patent exclusivity	Depended on the expiration of listed formulation and abuse-deterrence patents
Pediatric extension	Could extend qualifying patent or exclusivity periods if awarded
Settlement-controlled entry	Could permit an authorized or licensed launch before the last patent expiration
Regulatory approval timing	Depended on the ANDA stay and FDA review status

The key patent dates must be determined patent by patent from current USPTO and Orange Book records. A single “Hysingla ER expiration date” is not sufficient because different formulation patents can have different expiration dates and regulatory effects.

The core patent associated with the early litigation, U.S. Patent No. 8,337,886, was a formulation patent with an expiration period extending beyond the initial five-year NDA exclusivity window. That patent, rather than hydrocodone’s active-ingredient history, was the principal barrier addressed by the Alvogen litigation.

Did the case involve biosimilar risk?

No. Hysingla ER is a small-molecule drug, not a biologic. The case involved an ANDA and the Hatch-Waxman framework, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were:

• Generic hydrocodone extended-release tablets.
• Formulation design-around products.
• Authorized generic or licensed generic entry.
• Alternative extended-release opioids.
• Non-opioid pain treatments and abuse-deterrent opioid products.

How strong was Purdue’s Hysingla ER patent estate?

Purdue’s patent estate had meaningful commercial strength because it covered the product’s differentiated formulation rather than only a conventional hydrocodone tablet. Its strength rested on four factors.

Formulation specificity

Abuse-deterrent products often contain detailed claim limitations. Those limitations can narrow the claims but also make design-around analysis technically demanding.

FDA product matching

The ANDA applicant had to match the reference product’s dosage form and release profile closely enough to obtain approval. That regulatory constraint can reduce the practical room for a noninfringing formulation.

Multiple related patents

Continuation and related patents can create overlapping protection around composition, release behavior, and manufacturing characteristics. The estate was therefore broader than a single patent number, even though individual claims could be vulnerable.

Litigation leverage

The 30-month stay gave Purdue substantial timing leverage. Alvogen’s ability to obtain approval depended on the litigation schedule, the scope of the Paragraph IV challenge, and the terms of any settlement.

The principal weakness was the age and complexity of the underlying formulation technology. Prior-art references in controlled-release opioid formulations could support obviousness arguments, especially where the asserted claims combined known excipients or known release mechanisms.

What generic entry risks existed after the Alvogen settlement?

The case reduced immediate litigation uncertainty but did not eliminate generic-entry risk for Purdue. The principal scenarios were:

Scenario	Effect on Purdue
Settlement with delayed launch	Preserves revenue during the agreed period but creates a known future erosion date
Licensed generic entry	Reduces litigation cost but transfers part of the market to a generic product
Independent noninfringement success by another ANDA filer	Could weaken the patent estate and accelerate competition
Patent invalidity ruling in a parallel case	Could affect all Hysingla ER applicants
Design-around approval	Could create competition without direct infringement of the asserted claims
No successful generic approval	Maintains Purdue’s branded position until patent or exclusivity expiration

The commercial effect depends on whether Alvogen received a launch license, whether the agreement restricted launch timing, and whether other generic companies obtained independent approval. Settlement alone does not identify the economic terms.

How did this case compare with competing opioid patent disputes?

Hysingla ER litigation differed from conventional oxycodone or hydrocodone cases because Purdue relied heavily on abuse-deterrent formulation claims.

Issue	Hysingla ER	Conventional opioid product
Main patent asset	Abuse-deterrent formulation	Active ingredient, formulation, or method of use
Regulatory product	Extended-release hydrocodone tablet	May be immediate- or extended-release
Generic design-around difficulty	High when release and abuse-deterrence limits overlap	Often lower for simple formulations
Biosimilar pathway	Not applicable	Not applicable
Principal commercial barrier	Formulation patent and FDA product matching	Patent and regulatory exclusivity combination

Hysingla ER’s patent position was stronger than a simple salt or dosage patent if the claims captured the product’s release and abuse-deterrence behavior. It was also more exposed to invalidity and noninfringement arguments because formulation claims can contain numerous technical limitations.

Key Takeaways

• Purdue Pharma v. Alvogen Pine Brook involved a Paragraph IV challenge to Hysingla ER, an extended-release hydrocodone bitartrate tablet.
• The case was filed in the District of Delaware in 2015 under No. 1:15-cv-00687-GMS.
• U.S. Patent No. 8,337,886 was the principal patent associated with the dispute, with related Hysingla ER patents forming part of the broader estate.
• The litigation focused on formulation, controlled-release, and abuse-deterrence limitations.
• The case was resolved without a publicly reported final merits judgment invalidating Purdue’s patents or authorizing an unrestricted Alvogen launch.
• Any settlement or license terms were not publicly disclosed.
• Hysingla ER is a small-molecule drug, so biosimilar law does not apply.
• Generic-entry risk depended on patent expiration, settlement-controlled launch rights, parallel ANDA litigation, and potential formulation design-arounds.

FAQs

What was the Hysingla ER patent number in the Alvogen case?

The principal patent associated with the litigation was U.S. Patent No. 8,337,886. Related Hysingla ER patents, including U.S. Patent No. 8,808,737, formed part of Purdue’s broader formulation estate.

Did Alvogen win the Purdue Hysingla ER lawsuit?

The public docket does not show a final merits judgment holding Purdue’s asserted patents invalid or unenforceable. The case was resolved through a negotiated disposition.

Was Alvogen allowed to launch generic Hysingla ER?

The public case record does not establish an unrestricted launch authorization or disclose the commercial timing terms of any settlement.

Is Hysingla ER protected by a method-of-use patent?

The principal protection implicated in this litigation was formulation-based. Method-of-use and labeling patents must be evaluated separately through current Orange Book records and the specific ANDA certifications.

Does Purdue still have patent protection for Hysingla ER?

Purdue’s Hysingla ER protection depended on multiple patents with different expiration and listing profiles. The relevant current status must be assessed by reviewing each Orange Book-listed patent and any pediatric extension, terminal disclaimer, delisting, or post-settlement development.

References

1. U.S. District Court for the District of Delaware. (2015-2018). Purdue Pharma L.P. v. Alvogen Pine Brook LLC, No. 1:15-cv-00687-GMS. PACER docket.

2. U.S. Food and Drug Administration. (2014). Hysingla ER approval letter and prescribing information, NDA 206627. Center for Drug Evaluation and Research.

3. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,337,886, abuse-deterrent controlled-release dosage forms. Washington, DC.

4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,808,737, abuse-deterrent controlled-release dosage forms. Washington, DC.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.